Why ASOS Plc & AstraZeneca plc Are Bigger Bargains Than Centrica PLC

ASOS Plc (LON: ASC) is a better buy than Centrica PLC (LON:CNA) and AstraZeneca plc (LON:AZN), argues this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Centrica (LSE: CNA): double upgrade from underperform to outperform, target raised from 240p to 320p,” was the headline from Royal Bank of Canada (RBC) today. 

From sell to buy and all in one go. Are you impressed?

Be patient. With Centrica’s share price currently at 275p, that’s a 16% upside for a company that also offers a rich yield — but how does it compare with the capital gains that a growth company such as ASOS (LSE:ASC) or a defensive business such as AstraZeneca (LSE: AZN) could offer?  

Centrica: not cheap enough

Centrica is now RBC’s “preferred UK utility and among our favoured European names,” the broker said today, adding that it expects a compound annual growth rate for earnings at 6% and a strong free cash flow on the back of a stronger outlook for its retail operations.

The double upgrade boosted the stock, which was up 1.5% to 275p at the time of writing. 

My view is that Centrica is not cheap enough to deserve your attention right now. It’s as yet unknown if its core margins will expand in future, which is a key assumption for analysts at RBC.

Furthermore, its rather lowly valuation, which currently stands at about 10x forward earnings (P/E), fully reflects the risk of investing in it rather than the opportunity of securing a fantastic bargain, in my opinion. Even though Centrica chopped its divided earlier this year, dividend risk is alive and well, and there’s no growth in the business. 

I need growth potential to invest in equities, so one obvious name springs to mind here: ASOS!

ASOS: not too expensive

As I have argued in the past, ASOS could well be the right investment at 3,000p–3,500p a share if you’re looking for a growth candidate. Its stock currently trades at about 3,400p, which implies stellar forward P/E multiples of 80x and 60x, respectively, over the next two years.

Its balance sheet doesn’t carry any debts, while heavy capital requirements are low in the light of its core online business, so your full attention must be devoted to identifying trends for sales and margins — neither of which are very safe, in my opinion. But if ASOS manages to invest while growing its sales and margins over time, it’ll easily reward your efforts. 

In a conference call with analysts after quarterly results were announced earlier this month, chief financial office Nick Beighton discussed full-year 2015 guidance, arguing that he expected “sales to be towards the top-end of my range 15% to 20% range … while still maintaining our EBIT guidance of 4%.

Within that our strong period performance were largely gross margin flat year-over-year, accordingly we’ve accelerated investment in our people capability and our customer propositions.” 

We’ll see how this one goes. 

AstraZeneca: could become cheaper 

AstraZeneca stock is still overvalued by about 20%/25%, according to my calculations, but I’d probably bet on it rather than on the shares of Centrica. 

Why? I prefer Astra’s management team. 

Moreover, I never buy stocks that are cheap based on trading multiples, unless their fundamentals are attractive, but I am attracted to stocks that trade high based on low earnings projections, such as Astra’s stock. Quite simply, that’s because it may become much easier to beat estimates over time. 

If Astra meets market forecasts, it will unlikely deliver significant capital gains to its shareholders, but if its earnings profile improves, its rich valuation of almost 30x net earnings could become much more appealing. Astra’s interim results are due on Thursday and I suggest you keep an eye on them. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK owns shares in ASOS and has recommended Centrica. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Jumbo jet preparing to take off on a runway at sunset
Investing Articles

Down 70%+ since 2020, is IAG’s share price an unmissable bargain?

IAG’s share price is still down around 73% from its pre-Covid level, but with the business performing well last year,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£17,000 of shares in the FTSE 100 dividend giant can make me £18,874 every year in passive income!

This FTSE 100 dividend superstar has an 8.8% yield with dividends projected to rise. It looks very undervalued to me…

Read more »

Investing Articles

2 top UK growth stocks I’m buying for my Stocks and Shares ISA in July

Looking for UK-listed growth firms to add to a Stocks and Shares ISA? Our writer highlights two he's planning to…

Read more »

artificial intelligence investing algorithms
Investing Articles

This overvalued growth stock makes Nvidia look cheap!

ARM Holdings is a growth stock that’s benefitted from the AI rally. Muhammad Cheema takes a look at whether this…

Read more »

Investing Articles

1 penny stock I’d buy today while it’s 63p

This penny stock's down 70% since last March, yet could be set for a big comeback as the firm rebuilds…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Buying 8,617 Legal & General shares would give me a stunning income of £1,840 a year

Legal & General shares offer one of the highest dividend yields on the entire FTSE 100. Harvey Jones wants to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

£25k to invest? Here’s how I’d try to turn that into a second income of £12,578 a year!

If Harvey Jones had a lump sum to invest today he'd go flat out buying top FTSE 100 second income…

Read more »

Union Jack flag in a castle shaped sandcastle on a beautiful beach in brilliant sunshine
Investing Articles

2 lesser-known dividend stocks to consider this summer

Summer is here and global markets could be heading for a period of subdued trading. But our writer thinks there…

Read more »